Late-stage clinical biopharmaceutical company Sophiris Bio has received positive feedback from the European...
AstraZeneca and MSD report positive data from trial of Lynparza
AstraZeneca and MSD have reported positive results from the Phase III PROfound trial evaluating the safety and efficacy of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer (mCRPC).
Sophiris Bio receives positive feedback for prostate cancer trial
Late-stage clinical biopharmaceutical company Sophiris Bio has received positive feedback from the European Medicines Agency (EMA) for the Phase III localised prostate cancer clinical trial design.
Candel completes enrolment for trial of ProstAtak in prostate cancer
Biotechnology company Candel Therapeutics has completed the enrolment of patients choosing active surveillance (PrTK04 - NCT02768363) under the Ulysses trial, a Phase II study of ProstAtak for prostate cancer.
Phase I trial of male birth control pill reveals positive results
A new Phase I trial of a male birth control pill led by researchers at the University of Washington School of Medicine along with UCLA in the US has revealed successful results.
Merck plans Phase III trials for Keytruda in prostate cancer
Merck has announced plans to launch three pivotal Phase III clinical trials for its immunotherapy Keytruda as a combination treatment for prostate cancer after the drug demonstrated anti-tumour activity in an early-stage trial.
Janssen unblinds Phase III TITAN study for prostate cancer
Janssen Pharmaceutical Companies of Johnson & Johnson has unblinded the Phase lll TITAN trial investigating Erleada (apalutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
NIH to assess efficacy of male contraceptive skin gel
The US National Institutes of Health (NIH) has provided funding for a clinical trial to examine the effectiveness of male contraceptive skin gel NES/T.
Myovant Sciences completes enrolment for Phase III HERO trial
Myovant Sciences has completed patient enrolment for its Phase III HERO clinical trial assessing the safety and efficacy of relugolix for the treatment of advanced prostate cancer.
Male contraceptive pill limits sperm activity without side effects
Results of a preclinical study have shown that a new compound can immobilise sperm temporarily without side effects.
New study reports potential of DMAU as male birth control pill
Findings from a new study have demonstrated that the experimental male oral contraceptive, dimethandrolone undecanoate (DMAU), could be effectively used as a birth control pill for men.